Showing results (311-320 of 554) with videos related to
Sort By:
Pageof 56
Cancers|September 23, 2022
Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109Dongyu Zhang, Neil J Shah, Michael Cook, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaK Margolin, F R Aronson, M Sznol, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.Cancer Research|May 4, 2021
Targeting DDX3X Triggers Antitumor Immunity via a dsRNA-Mediated Tumor-Intrinsic Type I Interferon ResponseHyeongjwa Choi, Juntae Kwon, Min Soon Cho, et al.Journal of Cancer Survivorship : Research and Practice|April 4, 2022
Effect of exercise on body composition among women with ovarian cancerAnlan Cao, Brenda Cartmel, Fang-Yong Li, et al.Journal of Cancer Survivorship : Research and Practice|December 22, 2022
Exercise adherence in a randomized controlled trial of exercise on quality of life in ovarian cancer survivorsAnlan Cao, Brenda Cartmel, Fang-Yong Li, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Report on the ISBTC mini-symposium on biologic effects of targeted therapeuticsMichael B Atkins, David Carbone, George Coukos, et al.Urologic Oncology|February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503Raman Jay, R R McKay, L Werner, et al.Proceedings of the National Academy of Sciences of the United States of America|September 15, 1999
Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancerY Zhu, C Qi, S Jain, et al.Pageof 56